Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan-Reference-Cited by-同舟云学术

Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan

Published:2019-03-08 Issue:8 Volume:54 Page:742-751
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Takaguchi Koichi^ORCID,Toyoda Hidenori,Tsutsui Akemi,Suzuki Yoshiyuki,Nakamuta Makoto,Imamura Michio,Senoh Tomonori,Nagano Takuya,Tada Toshifumi,Tachi Yoshihiko,Hiraoka Atsushi,Michitaka Kojiro,Shibata Hiroshi,Joko Kouji,Okubo Hironao,Tsuji Kunihiko,Takaki Shintaro,Watanabe Tsunamasa,Ogawa Chikara,Chayama Kazuaki,Kumada Takashi,Kudo Masatoshi,Kumada Hiromitsu

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-019-01568-8.pdf

Reference23 articles.

1. Chayama K, Hayes CN. HCV drug resistance challenges in Japan: the role of pre-existing variants and emerging resistant strains in direct acting antiviral therapy. Viruses. 2015;7:5328–42.

2. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1 infection. Hepatology. 2014;59:2083–91.

3. Fujii H, Umemura A, Nishikawa T, et al. Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions. World J Hepatol. 2017;9:1064–72.

4. Sezaki H, Suzuki F, Hosaka T, et al. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings. Liver Int. 2017;37:1325–33.

5. Iio E, Shimada N, Abe H, et al. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. J Gastroenterol. 2017;52:94–103.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opportunities and challenges for the application of artificial intelligence paradigms into the management of endemic viral infections: The example of Chronic Hepatitis C Virus;Reviews in Medical Virology;2024-02-02

2. The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy;Current Drug Metabolism;2024-02

3. Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation;Expert Opinion on Pharmacotherapy;2022-11-17

4. Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection;Clinical Journal of Gastroenterology;2020-07-12

5. Diagnostic performance of real-time tissue elastography in chronic hepatitis C patients with sustained virological response;European Journal of Gastroenterology & Hepatology;2020-05